

## Erratum to: Cariprazine: First Global Approval

Paul L. McCormack<sup>1</sup>

Published online: 3 February 2016  
© Springer International Publishing Switzerland 2016

**Erratum to: Drugs (2015) 75:2035–2043**  
**DOI 10.1007/s40265-015-0494-7**

**Page 2038, Sect. 2.3.1 Schizophrenia, second paragraph, third sentence**, which previously read:

Risperidone 40 mg/day, which was included as an internal control for assay sensitivity, also reduced PANSS total score significantly more than placebo (−26.9 vs. −11.8;  $p \leq 0.001$ ).

Should read:

Risperidone 4.0 mg/day, which was included as an internal control for assay sensitivity, also reduced PANSS total score significantly more than placebo (−26.9 vs. −11.8;  $p \leq 0.001$ ).

---

The online version of the original article can be found under doi:[10.1007/s40265-015-0494-7](https://doi.org/10.1007/s40265-015-0494-7).

---

✉ Paul L. McCormack  
dru@adis.com

<sup>1</sup> Springer, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand